Zantac

The Delaware Supreme Court reversed the Superior Court's denial of defendants' Daubert motions in April 2025, excluding plaintiffs' expert testimony on general causation in In re Zantac (Ranitidine) Litigation, No. 255, 2024 (Del. Apr. 16, 2025). This follows GSK's reported October 2024 settlement of approximately 80,000 claims. Over 75,000 cases remain pending in Delaware Superior Court, with state court litigation continuing against GSK, Sanofi, Boehringer Ingelheim, and Pfizer after the federal MDL's December 2022 dismissal by Judge Robin L. Rosenberg in the Southern District of Florida.

The Eleventh Circuit has not yet ruled on plaintiffs' appeal of Judge Robin Rosenberg's December 2022 MDL 2924 dismissal that barred expert testimony and ended federal cases; oral arguments were held October 10, 2025. Connecticut bellwether trials are scheduled for March 14, 2028 per December 15, 2025 scheduling order, while Delaware's inventory faces renewed Daubert scrutiny after the Delaware Supreme Court's July 10, 2025 reversal requiring stricter expert evaluation.

Estimated 15 million US consumers; 100,000+ plaintiffs filed by October 2021; MDL Census Registry plus Delaware refiled claims suggest substantial claimant pool with active SOL windows in non-MDL jurisdictions post-December 2022 exclusion

• Delaware

  Delaware Superior Court C.A. No. N22C-09-101 — nearly 75,000 plaintiffs refiled personal injury claims after MDL exclusion; Delaware Supreme Court No. 255, 2024 affirmed jurisdiction July 10, 2025

• Southern District of Florida

  MDL No. 2924, 20-MD-2924 — Judge Robin L. Rosenberg presiding; Census Registry held tens of thousands of claimants; December 6, 2022 Daubert ruling excluded plaintiffs' general causation experts for five cancers, prompting Delaware refile

• Australia

  TGA testing of 135 batch samples — Aspen Zantac, Sandoz Ranitidine/Mylanta, Alphapharm RANI 2, Apotex, Arrow Pharma products recalled; NDMA levels above 0.3 ppm triggered suspension of all ranitidine registrations October 2020

• Singapore

  Health Sciences Authority recall of eight ranitidine brands September 16, 2019 — first regulatory action globally, preceding US/Canada/Switzerland recalls

MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) was created February 6, 2020; Daubert ruling excluded plaintiffs' general causation experts December 2022, triggering remand of remaining cases. No MDL-wide tolling order currently in effect. FDA requested market withdrawal of all ranitidine products April 1, 2020 due to NDMA contamination risk. State SOL accrual dates vary by jurisdiction; April 2020 FDA action serves as reference date for discovery-rule analysis in most states.